Sienna Biopharmaceuticals (SNNAQ) 10-Q 2018 Q2 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report onForm 10-Q of Sienna Biopharmaceuticals, Inc. (the “Company”) for the period ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of the Company, and John W. Smither, Chief Financial Officer of the Company, respectively, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2018	/s/ Frederick C. Beddingfield III
	Frederick C. Beddingfield III, M.D., Ph.D.
	President and Chief Executive Officer (Principal Executive Officer)
Date: August 9, 2018	/s/ John W. Smither
	John W. Smither
	Chief Financial Officer (Principal Financial Officer)